An international team of researchers led by Hudson Beyzavi of the University of Arkansas, is studying the use of platinum and gold to enable more effective forms of chemotherapy.
Gold-based complexes are not currently used in commercial cancer therapies. Cisplatin, a platinum-based chemotherapy drug, is commercially available, but it has several drawbacks.
“Biological importance of platinum complexes in medicinal chemistry has attracted considerable attention due to the wide-spread therapeutic activities of cisplatin,” the researchers said. “However, the anticancer properties of cisplatin are believed to be limited by major drawbacks, including intrinsic or acquired resistances and several toxicities.”
Beyzavi, an assistant professor in the Department of Chemistry and Biochemistry at the University of Arkansas, explained that new platinum- and gold-based drug candidates could lead to therapies that are more effective and less prone to resistance than cisplatin, which means patients could take lower doses, minimizing the risk of side effects. He said that another goal of this research is to expand the scope of cancer cells that can be targetted.
The researchers used computer simulations to design several different platinum-based molecular structures and test how these anti-cancer agents would bind to the DNA of cancer cells.
To synthesize the new gold-based molecular complexes, the researchers used structures called ligands — groups of atoms which can be added to metals. They focused on two types, isocyanide and thiolate ligands.
After the researchers had identified several promising molecular structures, Beyzavi synthesized the platinum and gold complexes. His collaborators then tested these drug candidates in the laboratory, exposing them to human lung, ovarian and breast cancer cell lines. Experimental results showed that these molecules were able to induce natural cell death by binding to the DNA of cancer cells. The researchers compared these new drug candidates to cisplatin and found that three of them were significantly more effective.
The team recently published their findings in the New Journal of Chemistry and Applied Organometallic Chemistry. Their articles were featured on the cover of both journals.
Hudson Beyzavi
Assistant Professor of Chemistry and Biochemistry
Hudson Beyzavi earned his Ph.D. in Organic Chemistry from Freie Universität Berlin. He worked on photosensitizer drugs for photodynamic therapy (PDT), a modern approach to cure cancer. He moved to Northwestern University as a Postdoctoral Awardee working on nanomaterials under the guidance of Sir Fraser Stoddart (2016 Nobel Prize Laureate) and Joe Hupp. In Fall 2017, Hudson joined the University of Arkansas from Harvard University and Massachusetts General Hospital where he was a Research Associate leading the Ritter Group. His research interests include transition metal-mediated reactions for PDT and positron emission tomography (PET) and utilizing epitaxially grown porous nanomaterials, e.g. metal–organic frameworks (MOF) and Covalent Organic Frameworks (COFs) as catalysts for nature-inspired and sustainable energy-related transformations.
